Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

* Inclusion Criteria * Diagnosis of advanced or metastatic NSCLC. Group A must be ALK negative NSCLC and Group B must be ALK positive NSCLC * Group A at least one prior regimen of therapy * Group B any number of prior regimens. * Mandatory tumor tissue available * At least one measurable lesion * ECOG Performance status 0 or 1 * Adequate bone marrow, renal, liver and pancreatic function * Negative pregnancy test for females of childbearing potential * Group B Phase 2: No prior systemic treatment for advanced or metastatic disease (adjuvant and/or neoadjuvant therapies are allowed if completed at least 6 months prior to study entry. No prior tyrosine kinase inhibitor therapy is allowed at any time prior to study entry) Exclusion Criteria: * No prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody. * No Severe or Chronic medical conditions including gastrointestinal abnormalities or significant cardiac history * No active infection requiring systemic therapy * Prior organ transplantation including allogenic stem cell transplantation.